Affordable Access

Access to the full text

Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China’s largest independent operator of pathology laboratories

Authors
  • Xie, Fengxiang1
  • Zhang, Liran1
  • Zhao, Dongman1
  • Wu, Xuefen2
  • Wei, Mingsong3
  • Zhang, Xuelian4
  • Wu, Xiaohui5
  • Fang, Hao6
  • Xu, Xue7
  • Yang, Meng8
  • Qi, Debo9
  • 1 Jinan KingMed Diagnostics, Department of Pathology, Jinan, Shandong Province, 250101, China , Jinan (China)
  • 2 Kunming KingMed Diagnostics, Department of Pathology, Kunming, Yunnan Province, 650000, China , Kunming (China)
  • 3 Guangxi KingMed Diagnostics, Department of Pathology, Nanning, Guangxi Autonomous Region, 530007, China , Nanning (China)
  • 4 Nanjing KingMed Diagnostics, Department of Pathology, Nanjing, Jiangsu Province, 250032, China , Nanjing (China)
  • 5 Chongqing KingMed Diagnostics, Department of Pathology, Chongqing, Chongqing Municipality, 400050, China , Chongqing (China)
  • 6 Changsha KingMed Diagnostics, Department of Pathology, Changsha, Hunan Province, 410205, China , Changsha (China)
  • 7 Hefei KingMed Diagnostics, Department of Pathology, Hefei, Anhui Province, 230088, China , Hefei (China)
  • 8 Zhengzhou KingMed Diagnostics, Department of Pathology, Zhengzhou, Henan Province, 450000, China , Zhengzhou (China)
  • 9 Jinan KingMed Diagnostics, Department of Genetics, Jinan, Shandong Province, 250101, China , Jinan (China)
Type
Published Article
Journal
BMC Infectious Diseases
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Nov 11, 2019
Volume
19
Issue
1
Identifiers
DOI: 10.1186/s12879-019-4614-y
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundHigh-risk human papillomavirus (HR-HPV) testing is more sensitive than cytology for the detection of cervical cancer and its precursors. However, limited and inconsistent data are available about the efficacy of the combination of these two methods for screening cervical adenocarcinoma. This multicenter retrospective study investigated the screening results of a cohort of Chinese patients who were subsequently diagnosed with invasive cervical adenocarcinoma, with the goal of identifying the optimal cervical adenocarcinoma screening method.MethodsWe retrospectively retrieved and analyzed the data from patients with histologically confirmed primary invasive cervical adenocarcinoma from eight local pathology laboratories operated by KingMed Diagnostics, the largest independent operator of pathology laboratories in China, over a 2-year period. Only patients who underwent cytology and/or HR-HPV testing within 6 months before the adenocarcinoma diagnosis were included. HR-HPV DNA was detected using one of two HPV test kits: the Hybrid Capture 2 (HC2) assay (Qiagen, Hilden, Germany) and an HPV genotyping panel (Yaneng Bio, Shenzhen, China).ResultsOf the 311 patients, 136 underwent cytology alone, 106 underwent HR-HPV testing alone, and 69 underwent cytology and HR-HPV co-testing. The sensitivities of cytology alone (64.0, 95% confidence interval [CI]: 55.9–72.0) and HR-HPV testing alone (66.0, 95% CI: 57.0–75.1) were similar (P = 0.738). The sensitivity of cytology and HR-HPV co-testing (87.0, 95% CI: 79.0–94.9) was significantly higher than that of either cytology (P = 0.001) or HR-HPV testing alone (P = 0.002).ConclusionsBoth cytology alone and HR-HPV testing alone showed poor screening efficiency, whereas the combination of the two clearly increased the efficiency of primary cervical adenocarcinoma screening. Thus, cytology and HR-HPV co-testing might be the most efficient cervical adenocarcinoma screening method.

Report this publication

Statistics

Seen <100 times